Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Sorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.81 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 0.81 |
| ▸ | RET known ✓ | P07949 | 4/20 | 0.81 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.81 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.81 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.81 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.81 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.81 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.81 |
| ▸ | ABL1 | P00519 | 3/20 | 0.81 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.81 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.81 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.81 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.81 |
| ▸ | HTR1A | P08908 | 2/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694648 | 0.93 | RAF1 (0.67) | RAF1KDRRETBRAFABL1 | |
| Hydrochloric Acid SCHEMBL1702120 | 0.92 | RAF1 (0.66) | RAF1KDRRETBRAFABL1 | |
| Sorafenib SCHEMBL19554804 | 0.92 | KDR (0.84) | RAF1KDRRETBRAFABL1 | |
| Hydrochloric Acid SCHEMBL1702492 | 0.91 | RAF1 (0.65) | RAF1KDRRETBRAFABL1 | |
| Sorafenib SCHEMBL14739751 | 0.90 | RAF1 (1.00) | RAF1KDRRETBRAFABL1 | |
| Sorafenib SCHEMBL8218 | 0.90 | RAF1 (1.00) | RAF1KDRRETBRAFABL1 | |
| Sorafenib SCHEMBL29349634 | 0.90 | RAF1 (1.00) | RAF1KDRRETBRAFABL1 | |
| Sulfuric Acid SCHEMBL2043327 | 0.89 | RAF1 (0.63) | RAF1KDRRETBRAFABL1 | |
| SCHEMBL1702479 | 0.89 | RAF1 (0.63) | RAF1KDRRETBRAFABL1 | |
| Sorafenib SCHEMBL1533982 | 0.89 | RAF1 (0.98) | RAF1KDRRETBRAFABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11788151-B2 | C-RAF mutants that confer resistance to RAF inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210388325-A1 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-11186874-B2 | ERK1 and ERK2 mutations that confer resistance to MAPK pathway inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190142830-A1 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20170268065-A1 | ERK1 and ERK2 Mutations That Confer Resistance to MAPK Pathway Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170204383-A1 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | EMERY CAROLINE (US) | 2017-07-20 | — | — | US | disclosed |
| US-9629839-B2 | C-RAF mutants that confer resistance to RAF inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20150133478-A1 | C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133478-A1 | C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885KDR 752/4885RET 43/4885 |
| US-20190142830-A1 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885KDR 752/4885RET 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.